Chronic respiratory diseases that affect the airways and different structures of the lungs are on the rise. As per an article in the journal Office of Disease Prevention and Health Promotion prevalence of asthma has been increasing since 1980.
Furthermore, COPD is believed to be one of the fourth main cause of death in North America. In 2006, about 120,000 succumbed to COPD in the U.S. This figure was close to the number of patients who lost their battle against lung cancer.
Last year, Jackson, Mississippi was declared as the “Allergy Capital” of the U.S. by experts in “Asthma and Allergy Foundation of America.” Researchers at Allied Market Research analyzing the share and size and growth in the COPD and asthma devices market say concerns over air pollution will open new avenues for the industry.
Big brands bank on billion dollar inhaler industry
The major announcement in the inhaler industry arrived when Elder Pharmaceuticals revealed that it is banking on the Rs. 800 Cr nasal inhaler category in India. This pharma company plans on strengthening its rural marketing plans and selling products through a strong distribution channel. Reduced price points as well as attractive packaging are believed to be some of the areas where inhaler manufacturers would be focusing more.
A company named Teva made winds in the COPD and asthma devices market, when it announced that the FDA has finally accepted to review the manufacturers new drug applications for two new products. The first salmeterol product is Teva’s fixed-dose combination ICS and LABA, which are delivered through the company’s RespiClick breath-actuated, MDPI. Another fluticasone propionate, which is an ICS monotherapy delivered through the RespiClick device, has also caught quite an attention.
New prototype nebulizer would soon replace injections
Nebulizers are not new. Medical practitioners have been using bulky and big electric nebulizers for the past 25 years to help kids’ breath without difficulty during an asthma attack.
However, an advanced prototype nebulizer developed in 2015 at the famous RMIT, Melbourne, completely revolutionized the COPD and asthma devices market. Designed to easily fit into a human hand the device can deliver a higher dose of drugs per minute than the current nebulizers available in the market.
Product developers behind this advanced device said that the product will soon replace the injections as well as traditional inhalers for patients with conditions such as diabetes, cancer, asthma and cystic fibrosis. The product developers further add that it is too early to say what the price of the product will be, but they hope it to be below $50 USD.
Ideally with the new version that’s affordable enough, their demand in developing nations such as India, Africa and others, where diseases are often spread through reuse of non-sterilized needles would increase.
R&D in the drug powder inhalers strengthens
Pulmonary as well as nasal delivery is a rapidly growing field. Growth in this segment is particularly driven by the dominance of several, chronic obstructive, particularly in developing countries such as the India, Africa and others. Furthermore, the dry powder-inhaler technology that uses engineered particles has also become the most preferred approach, when it comes to inhalation formulation over other aerosols as well as dry-powder technologies.
A company named “Capsugel’s Dosage Form Solutions” shot to fame when it made a huge investment in two important components required to administer an inhalation dosage forms for its end users. The company’s inhalation formulation as well as process design applies a particle—engineering production platform.
Another attraction is the manufacturer’s full range of engineered dry powder-inhaler capsule. Capsugel’s product is in its Phase 3 clinical manufacturing scales. They are also operating with equipment makers to design finished equipment as well as further optimize the solution. Such products will create new opportunities for many COPD and asthma devices market players.
Metered Dose Inhalers segment witnesses B2B deals
In 2016, the Metered Dose Inhaler segment will observe major business to business deals. Propeller Health has already set the stage by partnering with a drug delivery system brand called Aptar Pharma.
The investor took this bold step to become the first to the market connected, integrated metered dose inhaler company. Commenting on the recent development David Van Sickle, the CEO at the Propeller, said “Patients and physicians deserve better designed inhalers that are easier to use and help them successfully treat their chronic respiratory disease.”
“We are excited to work with Aptar to bring important digital innovation to respiratory drug delivery,” said Sickle. “We expect our connected inhaler to become the cornerstone for a platform of digital programs that will support and encourage better management of and quality of life with chronic respiratory disease. Together I believe we have the scale and expertise to impact millions of patients with asthma and COPD around the world.”
Ultrasonic nebulizer set to revolutionize the COPD and asthma devices market
Pocket size or small ultrasonic nebulizer applying a novel nozzle that can enhance inhalers are witnessing higher demand. Industry experts believe that inhalation has opened new routes for the non-invasive, drug delivery techniques, both local as well as systematic applications.
Besides this, excessive control over the particle size and with output is playing a critical part in ensuring the efficiency and effectiveness of the expensive drug delivery has caught the attention of various scientists and researchers.
A group of innovators from the Department of Electrical Engineering and Computer Science at the reputed University of California has invented novel equipment for inhalation drug delivery, which fulfils the requirements unmet by existing commercial devices. This is a clear indication that the future of the COPD and asthma devices market will remain robust in years to come.
Allied Market Research